黏合剂类药用辅料市场（2026—2031）
黏合剂类药用辅料市场规模预计由2026年的15.5亿美元增至2031年的19.4亿美元，预测期复合年增长率为4.58%。北美是当前最大市场，亚太地区增长最快。
市场研究正文
规模、增长、细分、驱动因素与关键问题
当前质量分 100.00，审核状态 accepted。结构化字段已按 RoboInd 内容层级组织。
核心结论
黏合剂类药用辅料市场规模预计由2026年的15.5亿美元增至2031年的19.4亿美元，预测期复合年增长率为4.58%。北美是当前最大市场，亚太地区增长最快。
市场走势
结构化指标
| 指标 | 年份 | 数值 | 性质 |
|---|---|---|---|
| 复合年增长率 | 2031 | 4.58% | 机构预测 |
| 市场规模 | 2026 | USD 1.55 billion | 机构预测 |
| 市场规模 | 2031 | USD 1.94 billion | 机构预测 |
细分市场份额
市场结构
| 维度 | 细分项 | 年份 | 份额 |
|---|---|---|---|
| application | tablets | 2025 | 37.860% |
| end_user | pharmaceutical companies | 2025 | 46.870% |
| geography | North America | 2025 | 43.650% |
| source | natural binders | 2025 | 57.650% |
关键结论
- application 维度中，tablets 在 2025 年的公开份额为 37.86%。
- end_user 维度中，pharmaceutical companies 在 2025 年的公开份额为 46.87%。
- geography 维度中，North America 在 2025 年的公开份额为 43.65%。
- source 维度中，natural binders 在 2025 年的公开份额为 57.65%。
主要参与者
- Ashland Inc.
- Roquette Frères
- BASF SE
- DFE Pharma GmbH & Co. KG
- JRS Pharma GmbH & Co. KG
增长驱动因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Growth Of Generic And Biosimilar Oral Solid Dose Manufacturing | +1.800% | Global, with concentrated gains in North America, India, and China | Short term (≤ 2 years) |
| Demand For Multifunctional And Co-processed Excipients | +1.200% | Global, strongest in North America and EU | Medium term (2-4 years) |
| Expansion Of Pharmaceutical And Nutraceutical Production In Asia-Pacific | +0.800% | Asia-Pacific core, with spillover to Middle East and Africa | Medium term (2-4 years) |
| Continuous Manufacturing And High-Shear Granulation Adoption | +0.600% | North America and EU, with early gains in India | Long term (≥ 4 years) |
| Excipient Traceability As A Procurement Differentiator | +0.400% | Global, with early enforcement in India, US, and EU | Short term (≤ 2 years) |
市场制约因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Complex And Regionally Variable Excipient Regulation | -0.500% | Global, with the greatest divergence across US, EU, China, and India | Long term (≥ 4 years) |
| High Qualification And Change-Control Costs | -0.400% | Global, concentrated among mid-sized generic manufacturers | Long term (≥ 4 years) |
| Potential Risks of Contamination or Adverse Reactions | -0.300% | Europe and Southeast Asia most exposed | Short term (≤ 2 years) |
报告关注的关键问题
What is the projected value of the binders excipients market by 2031?
It is projected to reach USD 1.94 billion by 2031, growing at a 4.6% CAGR from 2026.
Which source category leads binder excipient demand?
Natural binders led with 57.65% share in 2025 due to established pharmacopoeial status and broad regulatory acceptance.
Why are synthetic binders growing faster?
Synthetic binders are forecast to grow at 6.5% CAGR through 2031 because PVP and copovidone support consistent high-speed and continuous processing.
Which application uses the most binder excipients?
Tablets led applications with 37.86% share in 2025, supported by their scale, cost profile, and widespread use in oral drug delivery.
Why are CDMOs important buyers of binder excipients?
CDMOs are the fastest-growing end-user group at a 7.9% CAGR through 2031 because they manage development and production for multiple drug programs.
Which region will grow fastest through 2031?
Asia-Pacific is forecast to grow at 5.7% CAGR, supported by pharmaceutical production growth in India and China.
市场概览
- 增长最快市场：亚太地区
- 最大市场：北美
- 市场集中度：中等
查看来源：Mordor Intelligence